Peter Mac Testing Validates AlgoraeOS v2
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The results support the platform's use in future drug discovery and optimization programs, with plans for further investigation into promising combinations. The company will also initiate a multi-anchor combination pipeline to evaluate additional drug combinations identified through the validation process.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Algorae Pharmaceuticals Limited on 6ix
Story so far
Earlier from Algorae Pharmaceuticals
- Updated - NSW Health Public Hospital Supply Contract
- Algorae Awarded NSW Health Public Hospital Supply Contract
- Algorae Expands AI Drug Combination Pipeline
- 1AI Executes License & Supply Agreement with Torrent Pharma
- Algorae and Zydus Enter Exclusive Commercial Agreement
Later from Algorae Pharmaceuticals
- Quarterly Activities Report/Appendix 4C Cashflow Statement
- Appendix 4E and 2026 Annual Report
- Peter Mac partners with Algorae on 3rd AI validation program
- Algorae executes Licence & Supply Agreement with Umedica
- Quarterly Activities Report and Appendix 4C Cash Flow Report
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals